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OBJECTIVE: Spinocerebellar ataxias are neurodegenerative disorders involving the cerebellum and its connections.
There are more than 30 distinct subtypes, 16 of which are associated with an identified gene. The aim of the current
study was to evaluate a large group of patients from 104 Brazilian families with spinocerebellar ataxias.
METHODS: We studied 150 patients from 104 families with spinocerebellar ataxias who had received molecular
genetic testing for spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17, and dentatorubral-pallidoluysian atrophy. A
statistical analysis of the results was performed using basic descriptive statistics and the correlation coefficient (r),
Student’s t-test, chi-square test, and Yates’ correction. The statistical significance level was established for p-values
,0.05.
RESULTS: The results show that the most common subtype was spinocerebellar ataxia 3, which was followed by
spinocerebellar ataxia 10. Moreover, the comparison between patients with spinocerebellar ataxia 3,
spinocerebellar ataxia 10, and other types of spinocerebellar ataxia revealed distinct clinical features for each
type. In patients with spinocerebellar ataxia 3, the phenotype was highly pleomorphic, although the most
common signs of disease included cerebellar ataxia (CA), ophthalmoplegia, diplopia, eyelid retraction, facial
fasciculation, pyramidal signs, and peripheral neuropathy. In patients with spinocerebellar ataxia 10, the
phenotype was also rather distinct and consisted of pure cerebellar ataxia and abnormal saccadic eye movement as
well as ocular dysmetria. Patients with spinocerebellar ataxias 2 and 7 presented highly suggestive features of
cerebellar ataxia, including slow saccadic ocular movements and areflexia in spinocerebellar ataxia 2 and visual
loss in spinocerebellar ataxia 7.
CONCLUSIONS: Spinocerebellar ataxia 3 was the most common subtype examined, followed by spinocerebellar
ataxia 10. Patients with spinocerebellar ataxia 2 and 7 demonstrated highly suggestive features, whereas the
phenotype of spinocerebellar ataxia 3 patients was highly pleomorphic and spinocerebellar ataxia 10 patients
exhibited pure cerebellar ataxia. Epilepsy was absent in all of the patients with spinocerebellar ataxia 10 in this
series.
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INTRODUCTION
Spinocerebellar ataxias (SCA) represents a large and
complex group of heterogeneous autosomal dominant
degenerative diseases characterized by progressive degen-
eration of the cerebellum and its afferent and efferent
connections. Other nervous system structures are typically
affected, including the basal ganglia, brainstem nuclei,
pyramidal tracts, the posterior column and anterior horn
of the spinal cord, and the peripheral nerves (1-6).
SCA are clinically characterized by the presence of
cerebellar gait and limb ataxia (with dysmetria, dysdiado-
chokinesia, intention tremor, dysarthria, and nystagmus),
which may be accompanied by extracerebellar signs, such as
ophthalmoplegia, pyramidal signs, movement disorders
(including parkinsonism, dystonia, myoclonus, and chorea),
dementia, epilepsy, visual disorders (including pigmentary
retinopathy), and peripheral neuropathy (1-6).
SCA have a prevalence ranging from 1 to 5 cases per
100,000 individuals (7,8), and disease onset typically occurs
between 30 and 50 years of age, although cases developing
before the age of 20 and after the age of 60 have also been
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443described (2-10). The degenerative neuropathological pro-
cess has been studied in depth in transgenic mice and
Drosophila models (2-4,6,8). Neuroimaging, particularly
magnetic resonance imaging, typically reveals cerebellar
atrophy with or without brainstem involvement (olivopon-
tocerebellar atrophy) (2,3,4,6,9,10). Initially defined as
autosomal dominant cerebellar ataxias, SCA was subse-
quently classified by Harding into the following four basic
types: type 1, which is characterized by cerebellar ataxia
(CA) with optic atrophy, ophthalmoplegia, dementia,
amyotrophy, and extrapyramidal signs; type 2, involving
retinal degeneration and accompanied by ophthalmoplegia
and extrapyramidal signs; type 3, which is considered a
‘‘pure’’ type of CA; and type 4, which may present as
deafness and myoclonia in addition to CA (5).
With recent advances in molecular genetics, several SCA
genetic loci and genes have been identified on different
chromosomes, and these findings have enabled the applica-
tion of an improved classification system based on clinical
as well as genetic data (2,3,4,6,9-12).
Thirty-two different types of SCA have been identified
to date, and these are designated SCA1 to SCA36.
Dentatorubral-pallidoluysian atrophy (DRPLA) has also
been included in this group of disorders. The particular
gene responsible for each type of disease has been identified
for SCA types 1-3, 5-8, 10-15, 17, 27, 31, and DRPLA. The
remaining types (SCA 4, 18-23, 25, 26, 28-30, 32, 33-35, and
36) have been defined by linkage studies, as the associated
genes and mutations have not yet been identified
(2,3,4,6,9,10,11,12). Finally, it should be mentioned that
SCA types 9 and 24 remain undefined, and these two types
have been reserved for disorders yet to be described in the
literature. Additionally, SCA16 appears to be identical to
SCA15, and SCAs 29 and 15, as well as SCAs 22 and 19,
may represent different allelic forms of the same gene
(2,4,6,11,12). SCA3 is the most common form of the disease
worldwide, whereas the prevalence of types 1, 2, 6, 7, and 8
is varied depending upon the ethnic background of the
population (1,2,3,4,9-12).
The objective of this study was to evaluate the genotype-
phenotype correlations in 104 Brazilian families with SCA.
METHODS
Patients
We studied 150 patients from 104 families with SCA,
which had been extracted from a large Brazilian series of 190
SCA families (382 clinically affected family members and 296
patients evaluated by molecular genetic testing) and had
receivedpositive test resultsat theHospitalde Clı ´nicasof the
Federal University of Parana ´ in Curitiba,Brazil between1989
and 2009. The inclusion criteria included the following: 1) a
progressive clinical phenotype in which ataxia was the
prominent symptom; and 2) a positive familial history
compatible with autosomal dominant inheritance. All of
the patients were evaluated by at least one neurologist (HT)
using a standard protocol that assessed gender, age of onset,
duration of the disease, mean CAG or ATTCT polynucleo-
tide expansion, clinical manifestations (such as CA, ocular
movement disorders, visual loss, movement disorders,
pyramidal signs, peripheral nerve signs, cognitive dysfunc-
tion, or epilepsy), neuroimaging findings (brain CT and/or
MRI), and any additional findings. All of the patients
underwent routine laboratory tests, including CSF studies,
electroencephalography (EEG), nerve conduction velocity
with electromyography (NCV/EMG), and neuropsycholo-
gical tests (NPT) in selected cases. Signed informed consents
were obtained following a protocol approved by the
Institutional Ethics Committee of the Federal University of
Parana ´.
Genetic Analysis
Molecular diagnostic testing for SCA types 1, 2, 3, 6, 7,
and DRPLA was performed at the Centre for Research in
Neuroscience at the Montreal General Hospital Research
Institute of McGill University in Montreal, Quebec, Canada
between 1994 and 1998 (Prof. Guy Roleau, Dr. Izabel
Silveira, and Dr. Iscia Lopes-Cendes) and subsequently
(from 1998 to 2000) at the Medical Genetic Department of
UNICAMP (Prof. Iscia Lopes-Cendes). Molecular genetic
tests were performed from 2003 to the present at the
Molecular Biology Laboratory (Neurology Service, Hospital
de Clı ´nicas, Federal University of Parana ´: Prof. Lineu C.
Werneck) and Genetika Laboratory (Prof. Salmo Raskin) in
Curitiba/PR (SCA 1, 2, 3, 6, 7, 8, 12, and 17). Molecular
diagnostic tests for SCA10 were performed at the Baylor
DNA Diagnostic Laboratory (Baylor College of Medicine,
Houston, Texas, USA) (Prof. T. Ashisawa’s group) and
subsequently at the Galveston Department of Neurology
(University of Texas Medical Branch) (Prof. T. Ashizawa).
Peripheral blood was collected from patients and rela-
tives, and genomic DNA was isolated from peripheral blood
leukocytes using the standard technique (Sambrock et al.
1989, Cold Spring Harbor Laboratory Press, NY, USA) (13).
Expanded triplet repeats in the genes responsible for
SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA12, SCA17, and
DRPLA were amplified using the primer pairs Rep-1/Rep-2
(Orr et al. 1993), F-1/F-2 (Sanpei et al. 1996; Pulst et al. 1996),
MJD25/MJD52 (Kawaguchi et al. 1994), S-5-F1/S-5-R1
(Zhunchenko et al. 1997), 4U1024/4U716 (David et al.
1997), SCA8-F3/SCA8-R4 (Koob et al. 1999), PPP2R2B-A/
PPP2R2B-B (Holmes et al. 1999), TBP-F/TBP-R (Nakamura
et al. 2001) and CTG-B37 (699)/(840) (Koide et al. 1994),
respectively (2,3,4,6,9,10,11,12). The analysis of the ATTCT
repeat region within the SCA10 gene was performed by
polymerase chain reaction (PCR) amplification using the
primers attct-L (5’-AGAAAACAGATGGCAGAATGA-3’)
and attct-R (5’-GCCTGGGCAACATAGAGAGA-3’), as
previously described (11,14). Patient DNA samples that
showed a single, normal SCA10 allele by PCR underwent
Southern blot analysis to assess large expansion (14).
The identification of normal and expanded allele size was
based on previous reports, which had defined the following
conditions: for the SCA1 gene, affected alleles contain 40-82
CAG repeats (normal alleles demonstrate 6-39 CAG
repeats); for SCA2, affected alleles contain 33-64 repeats
(normal alleles have 14-31); in SCA3, affected alleles contain
54-86 repeats (normal alleles have 12-42); in SCA6, affected
alleles contain 19-30 repeats (normal alleles have 4-18); in
SCA7, affected alleles contain 37-200 repeats (normal alleles
have 4-27); in SCA8, affected alleles contain 107-127 repeats
(normal alleles have 16-91); in SCA12, affected alleles
contain 55-78 repeats (normal alleles have 7-32); in SCA17,
affected alleles contain 47-63 repeats (normal alleles have
25-44); and in DRPLA, affected alleles contain 49-79 CAG
repeats (normal alleles have 6-36) (2,3,4,6,9,10,11,12). In
SCA10, the pentanucleotide ATTCT repeat in the SCA10
gene was evaluated in reference to pathological expansion
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repeats) (14).
Statistical Analysis
The statistical analysis of the results was performed using
basic descriptive statistics and the correlation coefficient (r),
Student’s t-test, chi-square test, and Yates’ correction. The
level of statistical significance was set to p-values ,0.05.
RESULTS
Mutations were identified in 66.3% of the families and
were most frequently identified for SCA3 (72.46%). SCA10
represented the second most common type of SCA (11.60%),
followed by SCA2 (7.25%), SCA7 (4.34%), SCA1 (2.90%), and
SCA6 (1.45%).
Of the affected patients examined, the male to female
ratio was 1:1.2, and the age at onset ranged from 22 to 60
years with a mean onset at 35 years ¡6.2 years of age. Also,
the average length of time with disease for these patients
was 13.6¡10.7 years (variance of 1-32 years).
Table 1 shows a brief summary of the clinical data and the
neuroimaging findings for SCA types 1,2,3,6,7,10 as well as
overall SCA, excluding SCA10. This table also includes the
demographic, clinical, and molecular data for each form of
SCA.
In comparison to patients with SCA10, those with SCA3
presented more frequently with appendicular ataxia,
ophthalmoplegia, diplopia, facial fasciculations, eyelid
retraction (bulging eyes), severe hyperreflexia, severe
hypo/areflexia, and muscular fasciculations. Significant
differences (p,0.05) were also observed between these
two SCA types regarding the presence of Babinski’s sign,
spasticity, amyotrophy, and cognitive dysfunction. In
contrast, ocular dysmetria was significantly more frequently
seen in patients with SCA10.
In addition, when comparing patients with SCA10 to
those with all other forms of SCA (excluding SCA3), this
specific subtype presented more frequently with nystagmus
and ocular dysmetria, whereas ophthalmoplegia/paresis,
diplopia, slow saccadic movements, and hyporeflexia were
observed less commonly in patients with SCA10 than other
Table 1 - SCA Types 1, 2, 3, 6, 7, 10 - Clinical Data/Neuroimaging.
Clinical Data/Neuroimaging X SCA type: SCA1 SCA2 SCA3 SCA6 SCA7 SCA10
SCA
Total
Expansion CAG/ATTCT (mean) 48.5 45.66 70.27 24 64.8 1820 50.64
Patient number 4 12 101 1 5 27 123
Gender
Male 4 7 41 0 3 14 55
Female 0 5 60 1 2 13 68
Age of onset (mean) 33.75 34.17 34.87 43.0 28.4 35.00 34.83
Disease duration (mean) 7.65 6.16 8.65 9.0 7.80 13.60 7.85
Cerebellar Dysfunction
Gait Ataxia 4(100) 12(100) 100(99) 1(100) 5(100) 27(100) 122(100)
Appendicular Ataxia 1(25) 11(92) 92(9) 1(100) 1(20) 19(70.3) 106
Dysarthria 4(100) 12(100) 96(95) 1(100) 5(100) 27(100) 118
Ocular Movement Disorders
Nystagmus 4(100) 7(58) 98(97) 1(100) 3(60) 27(100) 112
Ocular Dysmetria 2(50) 2(16) 14(13.8) 0 1(20) 20(74) 19
Slow Saccadic Movement 0 12(100) 6(5.9) 0 1(20) 0 19
Ophthalmoplegia/paresis 4(100) 6(50) 90(89) 0 5(100) 0 105
Diplopia 2(50) 4(32) 61(60.4) 0 4(80) 0 71
Facial Fasciculations 1(25) 1(8) 42(41.6) 0 1(20) 0 45
Lid Retraction 2(50) 4(32) 88(87) 0 2((40) 3(11.1) 96
Visual Loss 0 0 0 0 5(100) 0 0
Movement Disorders
Parkinsonism 0 1(8) 8(7.9) 0 0 0 9
Dystonia 0 1(8) 12(11.9) 0 1(20) 0 14
Myoclonus 0 0 0 0 0 0 0
Chorea 0 0 0 0 0 0 0
Pyramidal Dysfunction
Babinski’s Sign 2(50) 0 20(19.8) 0 1(20) 0 23
Hyperreflexia 4(100) 0 69(68.3) 0 3(60) 518.5) 76
Spasticity 4(100) 0 32(31.7) 0 1(20) 3(11.1) 37
Peripheral Nerve Abnormalities
Hypo/areflexia 0 12(100) 22(21.8) 0 0 0 34
Amyotrophy 0 2(16) 17(16.8) 0 0 0 19
Paresis 0 0 0 0 0 0 0
Fasciculations 0 2(16) 22(21.8) 0 0 0 24
Exteroceptive Sensation Dysfunction 0 4(32) 12(11.9) 0 0 0 16
Proprioceptive Sensation Dysfunction 0 2(16) 5(4.9) 0 0 0 7
Cognitive Dysfunction 0 3(25) 0 0 1(20) 2(7.4) 4
Epilepsy 0 0 0 0 0 0 0
Neuroimaging: Cerebellar Atrophy: 4(100) 12(100) 96(95) 1(100) 5(100) 27(100) 118
NI:Cerebellar + BS Atrophy 0 1(8) 2(1.9) 0 0 1(3.7) 3
Others: Dysphagia 1(25) 2(16) 44(43.5) 0 1(20) 6(22.2) 48
SCA= Spinocerebellar Ataxia; NI= Neuroimaging; BS= Brainstem; SCA Total= All SCAs, without SCA10. (%)
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movements associated with hypo/areflexia are typically
suggestive of SCA2. As only one case of SCA6 was detected
in our patient sample, no comparisons between this subtype
and the other SCA subtypes could be made. The overall
results are presented in Table 2.
The neurological signs most commonly found in patients
with SCA3, SCA10, and other forms of SCA (SCA types 1, 2,
6, and 7) are summarized in Table 3.
DISCUSSION
In this sample of Brazilian patients with SCA, we
observed that SCA3, which is also known as Machado-
Joseph disease, was the most commonly identified subtype.
In fact, SCA3 is also the most commonly encountered SCA
worldwide, despite certain regional variations (SCA1 in
Italy, SCA2 in India and Cuba, and SCA7 in Sweden,
Finland, and South Africa) (2,3,4,6,9-12). In Brazil, several
previously published studies of patients with SCA have
identified SCA3 as occurring at the highest frequency
(9,10,12,15).
Surprisingly, in our patient series, SCA10 was the second
most frequently encountered SCA, accounting for approxi-
mately 12% of the cases. As the causative genetic mutation
for this subtype was discovered fairly recently, SCA10 was
not investigated prior to the year 2000 and was therefore
was not reported in the previously published SCA patient
series. Several other investigators (6,11,16) evaluated the
Table 2 - A comparative statistical analysis between the clinical data and neuroimaging results of patients with SCA3 x
SCA10 and SCA10 x other SCAs.
SCA3 X SCA10, SCA10 X Other SCAs
(X
2, p) SCA10 SCA3 X
2 p-value SCA10
Others
SCAs X
2 p-value
Patient Number 27 101 - - 27 22 - -
Cerebellar Dysfunction
Gait Ataxia 27 100 0.27 0.6037 27 22 - -
Appendicular Ataxia 19 92 7.94 0.0048 19 14 0.25 0.6171
Dysarthria 27 96 1.39 0.2383 27 22 - -
Ocular Movement Disorders
Nystagmus 27 98 0.82 0.3648 27 14 11.73 0.0006
Ocular Dysmetria 20 14 39.60 0.0000 20 5 12.79 0.0003
Slow Saccadic Movement 0 6 1.68 0.1946 0 13 21.72 0.0000
Ophthalmoplegia/paresis 0 90 81.04 0.0000 0 15 26.53 0.0000
Diplopia 0 61 31.15 0.0000 0 10 15.42 0.0001
Lid Retraction 3 88 59.91 0.0000 3 8 Y 3.11 0.0779
Facial Fasciculations 0 42 16.71 0.0000 0 3 Y 1.91 0.1672
Visual Loss 0 0 - - 0 5 Y
4.58
0.032
Movement Disorders
Parkinsonism 0 8 2.28 0.1310 0 1 1.25 0.2631
Dystonia 0 12 3.54 0.0599 0 2 2.56 0.1097
Myoclonus 0 0 - - 0 0 - -
Chorea 0 0 - - 0 0 - -
Pyramidal Dysfunction
Babinski’s Sign 0 20 6.34 0.0118 0 3 Y 1.91 0.1672
Hyperreflexia 5 69 21.66 0.0000 5 7 1.16 0.2816
Spasticity 3 32 4.54 0.0332 3 5 1.20 0.2739
Peripheral Nerve Abnormalities
Hypo/areflexia 0 22 7.10 0.0077 0 12 19.50 0.0000
Amyotrophy 0 17 5.24 0.0221 0 2 2.56 0.1097
Paresis 0 0 - - 0 0 - -
Fasciculations 0 22 7.10 0.0077 0 2 2.56 0.1097
Exteroceptive Sensation Dysfunction 0 12 3.54 0.0599 0 4 Y 3.20 0.0739
Proprioceptive Sensation Dysfunction 0 5 1.39 0.2383 0 2 2.56 0.1097
Cognitive Dysfunction 2 0 Y 3.55 0.0557 2 4 1.31 0.2525
Epilepsy 0 0 - - 0 0 - -
NI: Cerebellar Atrophy 27 96 1.39 0.2383 27 22 - -
NI: Cerebellar + BS Atrophy 1 2 0.28 0.5990 1 1 0.02 0.8822
Others: Dysphagia 6 44 Y 3.23 0.0723 6 4 0.12 0.7271
X
2 = Chi-Square Test; Y= Yates’s Correction; NI=Neuroimaging; BS=Brainstem; P=Probability (p,0.05).
Table 3 - The neurological signs most commonly
identified in patients with SCA10, SCA3, or other types
SCA.
SCA10 SCA3 Other SCAs
Neurological Signs
Appendicular Ataxia - + -
Nystagmus + - +
Ocular Dysmetria + --
Slow Saccadic Movement - - +
Ophthalmoplegia/paresis - ++
Diplopia - ++
Lid Retraction - + -
Facial Fasciculations - + -
Babinski’s Sign - + -
Hyperreflexia - + -
Spasticity - + -
Hypo/Areflexia - ++
Amyotrophy - + -
Fasciculations - + -
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American patients, although no cases were identified.
SCA10 was originally described in Mexican patients and
subsequently in Brazilian patients, and SCA10 represents
the second most common type of SCA after SCA2 (in
Mexico) and SCA3 (in Brazil) (6,11,17-19). Moreover, cases
of SCA10 have been detected in other Latin American
countries, including Argentina and Venezuela (19).
The other forms of SCA found in this patient series
consisted of SCA2, SCA7, SCA1, and SCA6. No cases of
DRPLA were found.
We initially compared the two most commonly identified
forms of SCA and found that several neurological signs
could be significantly correlated with either SCA3 or SCA10.
In general, clinical experience has demonstrated that SCA3
presents great phenotypic heterogeneity with large inter-
familial variation. However, the neurological signs identi-
fied in the current study (including ophthalmoplegia,
diplopia, facial fasciculations, eyelid retraction (bulging
eyes), spasticity, severe hyperreflexia, Babinski’s sign,
severe hypo/areflexia, amyotrophy, and muscular fascicu-
lations) reflect a more common phenotype among patients
with SCA3.
The genotype-phenotype correlation in SCA3 has been
the focus of several studies, and many of these published
results are identical to those reported in the present study
(20,21). Since the original description of SCA3 by Coutinho
and Andrade in 1978, which was followed by additional
studies from the same group, most investigators have
emphasized the presence of a characteristic phenotype
consisting of ophthalmoplegia, bulging eyes, facial fascicu-
lations, pyramidal signs, and peripheral neuropathy, as well
as dystonia in younger patients (20-22). More recently, the
observation of variant phenotypes for SCA3 has led to the
description of the following sub-phenotypes: subtype I
(with a predominance of extrapyramidal signs and dysto-
nia); subtype II (with CA and pyramidal tract signs);
subtype III (with CA and peripheral neuropathy signs);
subtype 4 (with parkinsonism); and subtype 5 (resembling
spastic paraplegia) (21). In contrast, the study by Scho ¨ls
et al. (23) describing German patients did not report the
typical signs described for Portuguese SCA3 cases, such as
bulging eyes, dystonia, and rigidity. In addition,
Klockgether et al. as well as other groups have suggested
that significant overlap exists between different SCAs,
which impedes the utility of purely clinical-based diagnoses
(4,24). Finally, other authors have attempted to describe
oculomotor phenotypes suggestive of several forms of SCA,
although these finding have no significant impact in regards
to daily clinical practice (25).
With respect to movement disorders in our patient series,
we observed that 15.3% of patients presented signs of
dystonia and parkinsonism (nine patients), and the majority
of these symptoms were presented by patients with SCA3.
Similar results have also been reported by Schols et al. and
Garcia Ruiz et al. (26,27).
The majority of patients with SCA10 in the current study
presented a phenotype of ‘‘pure’’ CA with occasional slight
pyramidal tract signs (hyperreflexia and discrete spasticity).
This presentation without epilepsy or peripheral neuropathy
differs from the phenotype described in Mexican patients,
who were shown to present with epilepsy in 72.2% of cases
and peripheral nephropathy in 66% of cases (28-32). These
observationshaveledtodebatesregardingthereasonforthese
different phenotypic manifestations in Mexican and Brazilian
SCA10 patients. The first explanation for these differences
correlated the observed phenotype with the expansion of the
ATTCT pentanucleotide repeat size (greater on average in
Mexicans) but was refuted in 2004 (11). Later, Matsuura et al.
(33) showed that the presence of a complex interruption
pattern composed of two different repeat interruptions,
ATTTTCT and ATATTCT, could explain the presence of a
phenotype consisting of epilepsy associated with CA.
More recently, Teive at al. evaluated the frequency of
epilepsy in a group of 80 patients from 10 Brazilian families
with SCA10 and identified the presence of epilepsy in only
3.75% of the cases, whereas case reports from Argentina and
Venezuela have presented a phenotype resembling those of
Mexican origin (18). Another interesting clinical aspect of
patients with SCA10 is that they generally do not present
ophthalmoplegia/paresis, although they do commonly
present nystagmus in lateral views and ocular dysmetria
(11,19,34).
Finally, we also evaluated the genotype-phenotype
correlation between patients with SCA10 and all other
types of SCA (excluding SCA3). These results demonstrated
that ophthalmoplegia/paresis and diplopia were the most
frequently observed signs in patients with other types of
SCA, including SCA 1, 2, and 7. However, the presence of
slow saccadic ocular movements and hypo/areflexia were
more common in patients with SCA2. These findings have
been repeatedly reported in the literature since the initial
description of SCA2 (3,4,6,35). Also, we should highlight
that the association between slow saccadic eye movements
and signs of peripheral neuropathy are highly suggestive, at
least from a clinical standpoint, of SCA2 (3,4,6,35). The same
is also true for the association between CA and vision loss
due to retinopathy in the case of SCA7 (3,4,6,35).
In our clinical setting, neither patients with SCA1 nor
SCA6 presented a characteristic phenotype, which was
likely due to the small number of cases identified.
SCA represents an extensive and complex group of
autosomal dominant neurodegenerative diseases, and to
date, SCA3, SCA1, SCA2, SCA6 and SCA7 are the most
frequently identified types of SCA worldwide. In this series
of Brazilian SCA patients, SCA3 was the most commonly
identified type, followed by SCA10. Upon comparisons
between SCA3, SCA10 and other SCAs, patients with each
of these conditions revealed several clinical features that may
be useful for the clinical classification of an affected patient or
family. In SCA3 patients, the phenotype was highly
pleomorphic, although CA, ophthalmoplegia, diplopia, eye-
lid retraction, facial fasciculation, pyramidal signs and
peripheral neuropathy were the most frequently observed
signs of disease. In SCA10 patients, the phenotype was rather
peculiar and consisted of pure CA, saccadic eye movement,
and ocular dysmetria. For the other SCAs, SCA2 and SCA7
exhibited highly suggestive phenotypes, presenting as CA
with slow saccadicocular movementsandprofound areflexia
in SCA2 and cerebellar ataxia and visual loss in SCA7. The
phenotypes of patients with SCA1, SCA6, and SCA10 were
commonly nonspecific (e.g., pure cerebellar ataxia).
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